Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
303 stopped studies mapped to Precursor Lymphoid Neoplasm and descendants · 86% state a reason
Over the 303 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01037764 | Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic…(AHCTALL) | Phase 2 | terminated | Dec 23, 2009 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01761682 | Acute Lymphoblastic Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT02428517 | Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia…(ATLAS2015) | — | terminated | Apr 28, 2015 | Asan Medical Center | The PI resigned the institute, and the rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood… | Phase 2 | terminated | Dec 10, 2012 | Weill Medical College of Cornell University | Slow accrual | Enrollment / accrual |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult… | Phase 1 | terminated | Jul 29, 2013 | ERYtech Pharma | Sponsor decision based off site/PI feedback about | Sponsor / business decision |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT02419469 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute… | Phase 2 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | — | terminated | Mar 31, 2011 | National Cancer Institute (NCI) | A replacement protocol was created to replace this current version of protocol. | Other (stated, no rule matched) |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | Phase 2 | withdrawn | Jul 14, 2010 | Stanford University | no accrual | Enrollment / accrual |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | Phase 1 / Phase 2 | terminated | Sep 6, 2010 | University College, London | Due to lack of biological efficacy and CD19 CAR CTL persistence | Efficacy / futility |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | Phase 2 | terminated | Jan 15, 2008 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine:… | Phase 2 | withdrawn | Oct 21, 2014 | Jazz Pharmaceuticals | not stated | Not stated |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged… | Phase 2 | terminated | Apr 17, 2015 | St. Jude Children's Research Hospital | Accrual goals were no longer feasible based on restrictions imposed by the DSMB. | Enrollment / accrual |
| NCT01685021 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic… | Phase 2 | terminated | Sep 13, 2012 | MorphoSys AG | not stated | Not stated |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01) | Phase 1 | terminated | Feb 27, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lack of accrual | Enrollment / accrual |
| NCT02578511 | Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With… | Phase 1 | withdrawn | Oct 19, 2015 | Ehab L Atallah | No enrollment, another competing study and difficult to find the right person to enroll on this… | Enrollment / accrual |
| NCT02815059 | Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and… | Phase 1 | withdrawn | Jun 28, 2016 | University of Utah | Termination of Investigator Initiated Studies using Ibrutinib | Investigator |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01312818 | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic… | Phase 2 | terminated | Mar 11, 2011 | Masonic Cancer Center, University of Minnesota | Slow accrual | Enrollment / accrual |
| NCT01207076 | AHN-12 Biodistribution in Advanced Leukemia | Phase 1 | terminated | Sep 22, 2010 | Masonic Cancer Center, University of Minnesota | Slow accrual | Enrollment / accrual |
| NCT02765997 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | Phase 2 | withdrawn | May 9, 2016 | Masonic Cancer Center, University of Minnesota | IRB Disapproval | Other (stated, no rule matched) |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in… | Phase 1 / Phase 2 | withdrawn | Jul 15, 2010 | Masonic Cancer Center, University of Minnesota | Replaced by a new study | Other (stated, no rule matched) |
| NCT01677949 | Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute… | Phase 2 | withdrawn | Sep 3, 2012 | Masonic Cancer Center, University of Minnesota | Slow accrual | Enrollment / accrual |
| NCT01383447 | Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory… | Phase 1 / Phase 2 | terminated | Jun 28, 2011 | National Cancer Institute (NCI) | This study was halted prematurely by the NCI for low accrual. | Enrollment / accrual |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT03141398 | Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in…(CGMs) | — | withdrawn | May 5, 2017 | Hamad Medical Corporation | Due to issues with study design | Other (stated, no rule matched) |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02647190 | Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed… | Phase 1 | withdrawn | Jan 6, 2016 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following… | Phase 2 | terminated | Oct 8, 2014 | St. Jude Children's Research Hospital | Investigator's decision. | Investigator |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With…(ORBIT) | Phase 1 / Phase 2 | withdrawn | Nov 25, 2016 | Celgene | Development of JCAR015 has been discontinued. No subjects were enrolled/treated under protocol… | Enrollment / accrual |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT02227108 | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia… | Phase 2 | terminated | Aug 27, 2014 | MedImmune LLC | The study was terminated prior to a planned interim analysis based on lack of required efficacy in… | Efficacy / futility |
| NCT02257684 | A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as… | Phase 2 | terminated | Oct 6, 2014 | Jazz Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin…(CICLODECH) | Phase 3 | terminated | Dec 13, 2012 | Hospital Israelita Albert Einstein | Lack of accrual | Enrollment / accrual |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell… | Phase 2 | terminated | Jun 18, 2012 | St. Jude Children's Research Hospital | Study was terminated in August 2016 due to replacement by a new study. | Other (stated, no rule matched) |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | Phase 2 | withdrawn | Jun 19, 2014 | Abramson Cancer Center at Penn Medicine | Did not enroll | Enrollment / accrual |
| NCT02129062 | Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic… | Phase 2 | terminated | May 2, 2014 | National Cancer Institute (NCI) | Slow accrual. | Enrollment / accrual |
| NCT02861040 | Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or… | Phase 1 | withdrawn | Aug 10, 2016 | Northwestern University | not stated | Not stated |
| NCT01401322 | Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic… | Phase 2 | terminated | Jul 25, 2011 | Stanford University | low accrual | Enrollment / accrual |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
| NCT00313053 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory… | Phase 1 | terminated | Apr 11, 2006 | Clare Twist | not stated | Not stated |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced… | Phase 2 / Phase 3 | withdrawn | Jul 7, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed… | Phase 1 / Phase 2 | terminated | Mar 20, 2009 | Novartis Pharmaceuticals | Despite considerable efforts to boost recruitment during the final year of the study, no new… | Enrollment / accrual |
| NCT01049113 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | Phase 1 | terminated | Jan 14, 2010 | Traws Pharma, Inc. | Lack of available clinical drug supply | Drug supply |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 20, 2018source: clinicaltrials